Table 1 Patient epidemiological and clinical data.
From: Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir
| Â | Â | Number of patients | Percentage |
|---|---|---|---|
HIV-2 group | A | 39 | 86.67 |
| Â | B | 6 | 13.33 |
Gender | Female | 24 | 53.33 |
| Â | Male | 21 | 46.67 |
Transmission | Heterosexual | 36 | 82.22 |
| Â | Homo-bisexual | 3 | 6.67 |
| Â | Transfusion | 2 | 4.44 |
| Â | MTCT | 2 | 2.22 |
| Â | IVDU | 1 | 2.22 |
| Â | unknown | 1 | 2.22 |
Country of origin | Europe | 10 | 22.22 |
| Â | Portugal | 4 | Â |
| Â | Belgium | 4 | Â |
| Â | France | 1 | Â |
| Â | Germany | 1 | Â |
| Â | Sub-Saharan Africa | 34 | 75.56 |
| Â | Mali | 17 | Â |
| Â | CapeVerde | 4 | Â |
| Â | Ivory Coast | 4 | Â |
| Â | Guinea | 2 | Â |
| Â | Guinea Bissau | 2 | Â |
| Â | DRCongo | 2 | Â |
| Â | Burkina Faso | 1 | Â |
| Â | Sub-Saharan unknown | 2 | Â |
| Â | Other: Nepal | 1 | 2.22 |
CDC Stage | A | 23 | 51.11 |
| Â | B | 9 | 20 |
| Â | C | 13 | 28.89 |
ARV therapy | Naive | 30 | 66.67 |
| Â | Treated (INI naive) | 15 | 33.33 |
| Â | NRTIs only | 6 | Â |
| Â | NRTI + PI | 8 | Â |
| Â | unknown | 1 | Â |
Age (years, median) | Â | 42 [12-78] | |
CD4 counts | Naïve | (cell/mm3) | |
|  | Mean, SD | 520 (± 303) | |
| Â | Median, range | 454 [30-1080] | |
|  | Treated (INI naïve) |  |  |
|  | Mean, SD | 331 (± 283) | |
| Â | Median, range | 286 [6-950] | |
Plasma viral load | Naïve | (copies/ml) | |
|  | Mean, SD | 36,304 (± 74,665) | |
| Â | Median, range | 5420 [Und-351,000] | |
|  | Treated (INI naïve) |  |  |
|  | Mean, SD | 94,293 (± 188,249) | |
| Â | Median, range | 11,350 [Und-540,000] | |